← Leaderboards
Robert L Truitt
Medical College Of Wisconsin
$1,772,126
Attributed
$1,772,126
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,772,126 · 4
By mechanism
R21$1,129,500 · 2
R01$415,835 · 1
S10$226,791 · 1
Top collaborators
No co-investigators on record.
Most similar at Medical College Of Wisconsin
Same institution · by research overlap
- Xue-Zhong Yu$18,834,259
- William R. Drobyski$18,734,918
- Joseph A Pidala$4,470,460
- Mary M Horowitz$184,978,306
- Cecilia J Hillard$13,181,596
Others in their field
Top investigators on “Graft Versus Host Disease”
- Mary M Horowitz · Medical College Of Wisconsin$91,475,733
- Bruce R. Blazar · University Of Minnesota$42,260,909
- Effie W Petersdorf · Fred Hutchinson Cancer Research Center$35,600,148
- Marcel R M Van Den Brink · Sloan-Kettering Institute For Cancer Res$31,342,499
- Pavan Reddy · University Of Michigan At Ann Arbor$27,447,362
- Leslie S Kean · Emory University$25,182,346
Research focus
Graft Versus Host DiseaseTissue /Cell CultureBone Marrow TransplantationTransplantation ImmunologyT LymphocyteHuman SubjectLaboratory MouseCellular ImmunityCell Population StudyStem Cell TransplantationThymusHematopoietic Stem CellsHematopoiesisPatient Oriented ResearchApoptosisGenetically Modified AnimalsPassive ImmunizationImmunoregulationLeukemiaLeukocyte Activation /TransformationCd AntigensDisease /Disorder Prevention /ControlBiological Signal TransductionMonoclonal Antibody
Grant awards (8)
CD200 Expression on Apoptotic DCs and Immune Tolerance$227,250
R21 · FY2005 · HL
CD200 Expression on Apoptotic DCs and Immune Tolerance$227,250
R21 · FY2004 · HL
Allospecific Immunoregulatory T Cells in BMT Recipients$225,000
R21 · FY2003 · HL
Allospecific Immunoregulatory T Cells in BMT Recipients$225,000
R21 · FY2002 · HL
Allospecific Immunoregulatory T Cells in BMT Recipients$225,000
R21 · FY2001 · HL
MECHANISMS IN SUCCESSFUL THERAPY OF GVHD WITH MOAB$210,990
R01 · FY2001 · CA
FACS VANTAGE/SE$226,791
S10 · FY2000 · RR
MECHANISMS IN SUCCESSFUL THERAPY OF GVHD WITH MOAB$204,845
R01 · FY2000 · CA